• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer

byMinjee Kim
March 17, 2023
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients allocated to the sotorasib group reported increased progression-free survival compared to the docetaxel group.

2. Sotorasib was generally tolerable with diarrhea being the most common severe adverse event.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Docetaxel is combined with immunotherapy to treat locally advanced non-small-cell lung cancer (NSCLC) with evidence of disease progression. A large proportion of patients with NSCLC report positive for KRASG12C mutations. In such cases, sotorasib – a molecule that irreversibly inhibits the KRASG12C protein – may be more effective. This randomized controlled trial aimed to compare the safety and efficacy of sotorasib with docetaxel in patients with KRASG12C-positive NSCLC who were previously treated with other anticancer drugs, such as platinum-based chemotherapy and immunotherapy. The primary outcome was progression-free survival while key secondary outcomes included overall survival, duration of response, and patient-reported outcomes. According to study results, sotorasib resulted in significantly improved clinical outcomes with greater progression-free survival compared with docetaxel. Overall, patients randomized to sotorasib reported fewer serious adverse events with diarrhea being the most common within this treatment group. This study was strengthened by a randomized design with patients from multiple countries, thus increasing its generalizability.

Click to read the study in The Lancet

Relevant Reading: Sotorasib for Lung Cancers with KRAS p.G12C Mutation

RELATED REPORTS

Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer

#VisualAbstract: Lobar vs Sublobar Resection for Peripheral Stage IA NSCLC

Risk model-based lung cancer screening is more cost effective than current practice

In-depth [randomized-controlled trial]: Between Jun 4, 2020, and Apr 26, 2021, 616 patients were assessed for eligibility across 148 centers in 22 countries. Included were patients ≥ 18 years with KRASG12C-positive locally advanced and unresectable or metastatic NSCLC. Altogether, 345 patients (171 in sotorasib and 175 in docetaxel) were included in the intention-to-treat analysis. The primary outcome of progression-free survival was significantly greater in the sotorasib group (5.6 months, 95% confidence interval [CI] 4.3-7.8) compared to the docetaxel group (4.5 months, 95% CI 3.0-5.7, hazard ratio [HR] 0.66, p=0.0017). There were fewer serious treatment-related adverse events among patients receiving sotorasib (n=18, 11%) compared to docetaxel (n=34, 23%). Overall, findings from this study were strongly in favor of sotorasib for treatment of locally advanced NSCLC with KRASG12C mutation.

 

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: docetaxelKRASKRASG12Clung cancerlung cancer treatmentnon-small cell lung cancernon-small cell lung cancer (NSCLC)nsclcsotorasib
Previous Post

Pituitary microadenomas exhibit slow growth and may require less frequent MRI surveillance

Next Post

#VisualAbstract: Routine invasive strategy not associated with improved outcomes in older adults with frailty and non-ST segment elevation acute myocardial infarction

RelatedReports

Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]
Chronic Disease

Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer

March 14, 2023
#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
StudyGraphics

#VisualAbstract: Lobar vs Sublobar Resection for Peripheral Stage IA NSCLC

March 10, 2023
Lessons from real-world implementation of lung cancer screening
Chronic Disease

Risk model-based lung cancer screening is more cost effective than current practice

February 20, 2023
Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients
Oncology

Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

January 9, 2023
Next Post

#VisualAbstract: Routine invasive strategy not associated with improved outcomes in older adults with frailty and non-ST segment elevation acute myocardial infarction

Intensive rehabilitation not superior to traditional therapy for arm function after stroke

2 Minute Medicine Rewind March 20, 2023

Psychiatric conditions less likely to be granted physician-assisted suicide

Dementia is associated with high rates of sleep-related breathing disorders

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stroke may be associated with sleep disturbances in adults
  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options